Design, Synthesis, and Antiviral Activity of the Thiazole Positional Isomers of a Potent HIV-1 Entry Inhibitor NBD-14270

被引:7
|
作者
Kurkin, Alexander, V [1 ]
Curreli, Francesca [2 ]
Iusupov, Ildar R. [1 ]
Spiridonov, Evgeniy A. [1 ]
Ahmed, Shahad [2 ]
Markov, Pavel O. [1 ]
Manasova, Ekaterina, V [1 ]
Altieri, Andrea [1 ]
Debnath, Asim K. [2 ]
机构
[1] EDASA Sci Srls, Via Stingi 37, I-66050 San Salvo, CH, Italy
[2] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Mol Modeling & Drug Design, 310 E 67th St, New York, NY 10065 USA
基金
美国国家卫生研究院;
关键词
Docking; HIV-1; gp120; NBD compounds; reverse transcriptase; thiazole isomers; IMMUNODEFICIENCY-VIRUS TYPE-1; FUSION INHIBITOR; CCR5; CORECEPTOR; NEUTRALIZATION; MARAVIROC; ENVELOPE; BINDING; OPTIMIZATION; ENFUVIRTIDE; ANTAGONIST;
D O I
10.1002/cmdc.202200344
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The envelope glycoprotein gp120 of human immunodeficiency virus type 1 (HIV-1) plays a critical role in virus entry to the cells by binding to the host cellular protein CD4. Earlier, we reported the design and discovery of a series of highly potent small-molecule entry antagonists containing a thiazole ring (Scaffold A). Since this thiazole ring connected with an ethyl amide linkage represents the molecule's flexible part, we decided to explore substituting Scaffold A with two other positional isomers of the thiazole ring (Scaffold B and C) to evaluate their effect on the antiviral potency and cellular toxicity. Here we report the novel synthesis of two sets of positional thiazole isomers of the NBD-14270 by retrosynthetic analysis approach, their anti-HIV-1 activity, cellular toxicity, and structure-activity relationships. The study revealed that Scaffold A provided the best HIV-1 inhibitors with higher potency and better selectivity index (SI).
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives as potent HIV-1 NNRTIs
    Liu, Zhaoqiang
    Tian, Ye
    Liu, Jinghan
    Huang, Boshi
    Kang, Dongwei
    De Clercq, Erik
    Daelemans, Dirk
    Pannecouque, Christophe
    Zhan, Peng
    Liu, Xinyong
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 140 : 383 - 391
  • [42] Design and synthesis of novel and potent allosteric HIV-1 integrase inhibitors with a spirocyclic moiety
    Adachi, Kaoru
    Manabe, Tomoyuki
    Yamasaki, Takayuki
    Suma, Akira
    Orita, Takuya
    Furuzono, Tomoko
    Adachi, Tsuyoshi
    Ohata, Yoshitsugu
    Akiyama, Yoshiyuki
    Miyazaki, Susumu
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 110
  • [43] Design and synthesis of bicyclic pyrimidinones as potent and orally bioavailable HIV-1 integrase inhibitors
    Muraglia, Ester
    Kinzel, Olaf
    Gardelli, Cristina
    Crescenzi, Benedetta
    Donghi, Monica
    Ferrara, Marco
    Nizi, Emanuela
    Orvieto, Federica
    Pescatore, Giovanna
    Laufer, Ralph
    Gonzalez-Paz, Odalys
    Di Marco, Annalise
    Fiore, Fabrizio
    Monteagudo, Edith
    Fonsi, Massimiliano
    Felock, Peter J.
    Rowley, Michael
    Summa, Vincenzo
    JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (04) : 861 - 874
  • [44] Design, synthesis and in-vitro evaluation of novel tetrahydroquinoline carbamates as HIV-1 RT inhibitor and their antifungal activity
    Chander, Subhash
    Ashok, Penta
    Zheng, Yong-Tang
    Wang, Ping
    Raja, Krishnamohan S.
    Taneja, Akash
    Murugesan, Sankaranarayanan
    BIOORGANIC CHEMISTRY, 2016, 64 : 66 - 73
  • [45] Co-delivery of HIV-1 entry inhibitor and nonnucleoside reverse transcriptase inhibitor shuttled by nanoparticles: cocktail therapeutic strategy for antiviral therapy
    Li, Wen
    Yu, Fei
    Wang, Qian
    Qi, Qianqian
    Su, Shan
    Xie, Lan
    Lu, Lu
    Jiang, Shibo
    AIDS, 2016, 30 (06) : 827 - 837
  • [46] Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region
    Eckert, DM
    Kim, PS
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (20) : 11187 - 11192
  • [47] Phosphoramidate derivatives of acyclovir: Synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro
    Zakirova, Natalia F.
    Shipitsyn, Alexander V.
    Jasko, Maxim V.
    Prokofjeva, Maria M.
    Andronova, Valeria L.
    Galegov, Georgiy A.
    Prassolov, Vladimir S.
    Kochetkov, Sergey N.
    BIOORGANIC & MEDICINAL CHEMISTRY, 2012, 20 (19) : 5802 - 5809
  • [48] Potent Activity of the HIV-1 Maturation Inhibitor Bevirimat in SCID-hu Thy/Liv Mice
    Stoddart, Cheryl A.
    Joshi, Pheroze
    Sloan, Barbara
    Bare, Jennifer C.
    Smith, Philip C.
    Allaway, Graham P.
    Wild, Carl T.
    Martin, David E.
    PLOS ONE, 2007, 2 (11):
  • [49] Synthesis of alpha-glucosidase I inhibitors showing antiviral (HIV-1) and immunosuppressive activity
    VandenBroek, LAGM
    KatVandenNieuwenhof, MWP
    Butters, TD
    VanBoeckel, CAA
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 1996, 48 (02) : 172 - 178
  • [50] IMPROVED SYNTHESIS OF (-)-CARBOVIR, GR90352X, A POTENT AND SELECTIVE INHIBITOR OF HIV-1 INVITRO
    JONES, MF
    MO, CL
    MYERS, PL
    PATERNOSTER, IL
    STORER, R
    WEINGARTEN, GG
    WILLIAMSON, C
    ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, 1990, 616 : 535 - 537